Esorubicin in advanced endometrial cancer

an ineffective and potentially toxic therapy - A Southwest Oncology Group study

Jacob B. Green, Stephanie Green, Robert V. O'Toole, David S Alberts, William A. Nahhas, Darryl L. Wallace

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Southwest Oncology Group conducted a phase II study of esorubicin treatment in patients with advanced endometrial cancer who had received no prior chemotherapy. Twenty of 31 patients were fully evaluable for response and toxicity. There were no clinical responses to treatment and 60% (12/20) of the patients developed severe or life threatening leukopenia on therapy. One evaluable patient was removed from study after a cumulative dose of 150 mg/M2 due to a reduction in left ventricular ejection fraction on MUGA scan and another developed congestive heart failure several months after discontinuation of treatment. Esorubicin has significant toxicity and limited clinical activity in patients with advanced endometrial cancer.

Original languageEnglish (US)
Pages (from-to)191-193
Number of pages3
JournalInvestigational New Drugs
Volume9
Issue number2
DOIs
StatePublished - May 1991

Fingerprint

Poisons
Endometrial Neoplasms
Therapeutics
Leukopenia
Stroke Volume
Heart Failure
esorubicin
Drug Therapy

Keywords

  • cardiac toxicity
  • chemotherapy
  • endometrial cancer
  • esorubicin

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Esorubicin in advanced endometrial cancer : an ineffective and potentially toxic therapy - A Southwest Oncology Group study. / Green, Jacob B.; Green, Stephanie; O'Toole, Robert V.; Alberts, David S; Nahhas, William A.; Wallace, Darryl L.

In: Investigational New Drugs, Vol. 9, No. 2, 05.1991, p. 191-193.

Research output: Contribution to journalArticle

Green, Jacob B. ; Green, Stephanie ; O'Toole, Robert V. ; Alberts, David S ; Nahhas, William A. ; Wallace, Darryl L. / Esorubicin in advanced endometrial cancer : an ineffective and potentially toxic therapy - A Southwest Oncology Group study. In: Investigational New Drugs. 1991 ; Vol. 9, No. 2. pp. 191-193.
@article{524de34ca5d347d383a7ad7005bef79d,
title = "Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy - A Southwest Oncology Group study",
abstract = "The Southwest Oncology Group conducted a phase II study of esorubicin treatment in patients with advanced endometrial cancer who had received no prior chemotherapy. Twenty of 31 patients were fully evaluable for response and toxicity. There were no clinical responses to treatment and 60{\%} (12/20) of the patients developed severe or life threatening leukopenia on therapy. One evaluable patient was removed from study after a cumulative dose of 150 mg/M2 due to a reduction in left ventricular ejection fraction on MUGA scan and another developed congestive heart failure several months after discontinuation of treatment. Esorubicin has significant toxicity and limited clinical activity in patients with advanced endometrial cancer.",
keywords = "cardiac toxicity, chemotherapy, endometrial cancer, esorubicin",
author = "Green, {Jacob B.} and Stephanie Green and O'Toole, {Robert V.} and Alberts, {David S} and Nahhas, {William A.} and Wallace, {Darryl L.}",
year = "1991",
month = "5",
doi = "10.1007/BF00175088",
language = "English (US)",
volume = "9",
pages = "191--193",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Esorubicin in advanced endometrial cancer

T2 - an ineffective and potentially toxic therapy - A Southwest Oncology Group study

AU - Green, Jacob B.

AU - Green, Stephanie

AU - O'Toole, Robert V.

AU - Alberts, David S

AU - Nahhas, William A.

AU - Wallace, Darryl L.

PY - 1991/5

Y1 - 1991/5

N2 - The Southwest Oncology Group conducted a phase II study of esorubicin treatment in patients with advanced endometrial cancer who had received no prior chemotherapy. Twenty of 31 patients were fully evaluable for response and toxicity. There were no clinical responses to treatment and 60% (12/20) of the patients developed severe or life threatening leukopenia on therapy. One evaluable patient was removed from study after a cumulative dose of 150 mg/M2 due to a reduction in left ventricular ejection fraction on MUGA scan and another developed congestive heart failure several months after discontinuation of treatment. Esorubicin has significant toxicity and limited clinical activity in patients with advanced endometrial cancer.

AB - The Southwest Oncology Group conducted a phase II study of esorubicin treatment in patients with advanced endometrial cancer who had received no prior chemotherapy. Twenty of 31 patients were fully evaluable for response and toxicity. There were no clinical responses to treatment and 60% (12/20) of the patients developed severe or life threatening leukopenia on therapy. One evaluable patient was removed from study after a cumulative dose of 150 mg/M2 due to a reduction in left ventricular ejection fraction on MUGA scan and another developed congestive heart failure several months after discontinuation of treatment. Esorubicin has significant toxicity and limited clinical activity in patients with advanced endometrial cancer.

KW - cardiac toxicity

KW - chemotherapy

KW - endometrial cancer

KW - esorubicin

UR - http://www.scopus.com/inward/record.url?scp=0025825533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025825533&partnerID=8YFLogxK

U2 - 10.1007/BF00175088

DO - 10.1007/BF00175088

M3 - Article

VL - 9

SP - 191

EP - 193

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -